Sani H Kizilbash
Mayo Clinic in Rochester · Mayo Clinic Cancer Center LAO
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sani H Kizilbash as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:09 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07708961 · Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype GlioblastomaMayo Clinic · recruiting · Glioblastoma, IDH-Wildtype · principal investigator
- Ph1NCT04197934 · WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System MetastasesMayo Clinic · active not recruiting · Anaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, IDH-Wildtype, Metastatic Lung Non-Small Cell Carcinoma · principal investigator
- Ph1NCT03528642 · Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic AstrocytomaNational Cancer Institute (NCI) · active not recruiting · Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Phase I study to evaluate safety, tolerability, pharmacokinetics and anti-tumor activity of WSD0922-FUR01FD007288 · FDA · MAYO CLINIC ROCHESTER · fiscal years 2021 to 2024 · $297,510 awarded in 2024Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- NCI Experimental Therapeutics-Clinical Trials Network with Phase 1 EmphasisUM1CA186686 · NCI · MAYO CLINIC ROCHESTER · PI ALEX A. ADJEI · fiscal years 2014 to 2019Named on NCT03528642
- Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTNUM1CA186709 · NCI · DANA-FARBER CANCER INST · PI KEITH T FLAHERTY, DONALD W. KUFE, Geoffrey I. Shapiro · fiscal years 2014 to 2026Named on NCT03528642
Most cited trial papers
Clinical-trial papers with this author name in glioma, ranked by citations from NIH iCite, fetched 2026-11-12 12:09 UTC. The ranking covers the 200 most relevant of 5 PubMed records, and a shared surname and initials can bring in a namesake. All 5 on PubMed
- Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.JAMA Oncol · 202434 citationsRCR 3.6
- Efficacy of Treatment With Armodafinil for Cancer-Related Fatigue in Patients With High-grade Glioma: A Phase 3 Randomized Clinical Trial.JAMA Oncol · 202230 citationsRCR 2.3
- Initial results of a phase II trial of 18F-DOPA PET-guided re-irradiation for recurrent high-grade glioma.J Neurooncol · 202217 citationsRCR 1.7
- Final Results from a First-in-Human Phase I Study of the Dual Isocitrate Dehydrogenase (IDH) 1/2 Inhibitor, LY3410738, in Advanced Solid Tumors Harboring IDH1 or IDH2 Mutations.Clin Cancer Res · 20257 citationsRCR 1.3
- STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.J Clin Oncol · 20265 citationsRCR 2.5